INTRODUCTION
============

Of fundamental importance to developmental biology and medicine is the question of whether postnatal growth or regeneration of a tissue recapitulates the molecular mechanisms of its embryonic development. The answers are complex and variable across different tissues. For example, both bone formation and fracture repair require BMP-Smad signaling, although the relevant BMP ligands themselves differ between these processes ([@b44-0050503]). By contrast, although the development of skeletal muscle progenitor cells requires *Pax3* and *Pax7*, these transcription factors are dispensable for regeneration by adult muscle stem cells ([@b31-0050503]).

Addressing these questions in the pancreas, a bifunctional organ comprising anatomically distinct endocrine and exocrine cell types, has implications for several devastating diseases, including diabetes, pancreatitis and pancreatic cancer. Lineage-tracing studies in the mouse have recently converged upon the finding that, although endocrine islet cells are generated de novo in the embryonic pancreas, their postnatal maintenance and replenishment relies instead on the proliferation of differentiated cells ([@b15-0050503]; [@b27-0050503]; [@b50-0050503]). With respect to mechanism, several genes that are dispensable for embryonic islet development but are required for the expansion of insulin-producing β-cells after birth have been identified in mice ([@b7-0050503]; [@b19-0050503]; [@b28-0050503]; [@b42-0050503]; [@b63-0050503]). A further distinction between physiological and regenerative growth is suggested by the regeneration-specific β-cell defect observed in mice lacking the *Glp1r* gene ([@b11-0050503]). Such a distinction might also apply to exocrine acinar cells, in which genes including *Notch1* and the hedgehog signaling component *Smo* are dispensable for normal development and homeostasis but are required for regeneration following caerulein-induced pancreatitis ([@b17-0050503]; [@b48-0050503]). In the present study, we address the postnatal role of a gene that is required for acinar cell development, β-catenin (*Ctnnb1*) ([@b39-0050503]; [@b58-0050503]).

Using the Cre-*loxP* system, we and others have previously shown that deletion of β-catenin, an essential component of the Wnt signaling pathway, abrogates acinar cell specification and development in mice ([@b39-0050503]; [@b58-0050503]). We have further shown that this gene is dispensable for the survival and phenotypic maintenance of adult acinar cells, as well as for the function of adult insulin-producing β-cells ([@b39-0050503]). Additional studies of Wnt--β-catenin signaling -- using distinct methodologies -- suggest a more complicated and context-dependent role for β-catenin. For example, other investigators have reported a pancreatitis-like phenotype in postnatal β-catenin knockout pancreata ([@b14-0050503]; [@b38-0050503]; [@b58-0050503]), suggesting that this gene is required not only for differentiation of acinar cells but also for their normal maintenance. Depending on the experimental design, hyperactivation of Wnt--β-catenin signaling can cause pancreatic agenesis, acinar cell hyperplasia or islet cell hyperplasia ([@b23-0050503]; [@b45-0050503]; [@b54-0050503]). Finally, inhibiting Wnt signaling in β-cells specifically is reported to impair their proliferation and glucose homeostasis function ([@b8-0050503]; [@b45-0050503]). These seemingly contradictory results suggest that the phenotype of β-catenin deletion in the pancreas is surprisingly dependent on the precise spatiotemporal domain of Cre activity.

With respect to the role of β-catenin in postnatal acinar cells, most previous studies have used Cre transgenes that are active throughout the developing pancreas, raising the possibility of non-cell-autonomous effects. By contrast, our own previous finding that β-catenin is dispensable in differentiated acinar cells was made in the uninjured adult pancreas ([@b39-0050503]), where basal levels of proliferation and apoptosis are so low that alterations due to loss of β-catenin could go undetected. In the present study, we address the postnatal requirements for β-catenin under conditions of rapid as well as gradual cellular turnover and expansion. We find that β-catenin is indispensable for physiological and regenerative proliferation of acinar cells, but dispensable for their survival and phenotypic maintenance. Together, this work identifies a continuous requirement for β-catenin in acinar development, extending from specification in the embryo to self-renewal in the juvenile and regeneration in the adult.

RESULTS
=======

Deletion of β-catenin in the adult pancreas does not compromise acinar cell maintenance
---------------------------------------------------------------------------------------

To establish a system in which the fate of β-catenin-deficient acinar cells could be directly and quantitatively compared to those of corresponding wild-type cells, we crossed mice carrying both a null allele of β-catenin and a deleter transgene, *Elastase-CreERT* ([@b39-0050503]; [@b52-0050503]) (*Ctnnb1^Δ/+^; ElaCreERT* mice), to mice that were double-homozygous for a conditional allele of β-catenin ([@b4-0050503]) and a Cre-dependent EYFP reporter construct ([@b51-0050503]) (*Ctnnb1^lox/lox^; R26R^EYFP/EYFP^* mice). The *ElaCreERT*-containing offspring of this cross are genetically matched except for β-catenin: they are heterozygous either for the conditional and wild-type alleles (*Ctnnb1^lox/+^; R26R^EYFP/+^; ElaCreERT*) or for the conditional and null alleles (*Ctnnb1^Δ/lox^; R26R^EYFP/+^; ElaCreERT*). The former genotype permits tamoxifen-inducible EYFP labeling of acinar cells without β-catenin deficiency and is henceforth referred to as 'control'. The latter permits simultaneous deletion of β-catenin and EYFP marking, and is henceforth referred to as 'ABKO', for acinar-specific β-catenin knockout. In principle, by comparing identically treated control and ABKO mice, we should detect a requirement for β-catenin in proliferation or survival as a relative decrease in the EYFP labeling indices of ABKO pancreata compared with those of controls.

To assess the functionality of this approach, we administered 10 mg tamoxifen to adult control or ABKO mice ('pulse') and analyzed EYFP labeling after 10 days ('chase'). As described in the Methods, we used quantitative immunofluorescence to compare the EYFP labeling index, between genotypes, of amylase-expressing acinar cells. We found widespread EYFP expression (\>50%) by acinar cells of both control and ABKO mice ([Fig. 1A,B](#f1-0050503){ref-type="fig"}), with indistinguishable labeling indices between the genotypes ([Fig. 1C](#f1-0050503){ref-type="fig"}). Immunofluorescence confirmed that EYFP-positive (EYFP+) acinar cells of ABKO pancreata were negative for β-catenin ([Fig. 1D--G](#f1-0050503){ref-type="fig"}), allowing us to use EYFP as a surrogate marker for the deletion of β-catenin. Pancreata from control and ABKO mice that did not receive tamoxifen \[harvested at postnatal day 60 (P60)\] exhibited a low amount of acinar cell EYFP labeling \[control (*n*=3): 4.8±2.3%; ABKO (*n*=3): 4.0±0.8%; *P*=0.8\], resulting from leakiness of the *ElaCreERT* transgene. As expected from our previous work ([@b39-0050503]), EYFP-labeled ABKO acinar cells were outwardly indistinguishable from controls, with normal expression of the epithelial junction protein E-cadherin ([Fig. 1H--K](#f1-0050503){ref-type="fig"}) and normal polarity, as indicated by the apical localization of amylase-containing secretory granules ([Fig. 1L--O](#f1-0050503){ref-type="fig"}).

![**Establishing a system to trace the fate of wild-type and β-catenin-deficient acinar cells.** Control (*Ctnnb1^lox/+^; R26R^EYFP/+^; ElaCreERT*) and acinar-specific β-catenin knockout (ABKO: *Ctnnb1^Δ/lox^; R26R^EYFP/+^; ElaCreERT*) mice received tamoxifen at 2 months of age and were analyzed 10 days later by immunofluorescence on frozen sections. (A,B) EYFP (green) is widely expressed in amylase+ acinar cells (red), indicating successful recombination. Scale bar: 100 μm. (C) Overall EYFP labeling of acinar cells does not differ between genotypes, 10 days post-tamoxifen (*n*=2 mice per genotype; *P*=0.48). (D--G) In controls, β-catenin localizes normally to the cell membrane of EYFP+ acinar cells, whereas, in ABKO pancreata, EYFP marks cells that have lost β-catenin expression. (H--K) E-cadherin exhibits identical membrane localization in EYFP+ acinar cells of control and ABKO mice, suggesting that loss of β-catenin does not perturb cell-cell adhesion. (L--O) Expression and apical localization of amylase is identical in control and β-catenin-deficient cells, indicating that loss of β-catenin does not affect acinar polarity or differentiation state.](DMM007799F1){#f1-0050503}

These results indicate that our experimental design can be used to compare acinar cell maintenance between genotypes, in terms of both number and phenotype. They also confirm that β-catenin is dispensable for the survival of acinar cells and the maintenance of their differentiated state, contrasting with its essential requirement during development ([@b39-0050503]).

β-catenin-deficient acinar cells do not contribute to postnatal expansion of the exocrine compartment
-----------------------------------------------------------------------------------------------------

The adult mouse pancreas is a highly quiescent organ, and very few acinar cells would be expected to divide during the course of the preceding experiment (≤2% per day) ([@b34-0050503]; [@b56-0050503]). Acinar cells divide much more rapidly shortly after birth, as the entire organism grows in mass and cellularity ([@b34-0050503]), and we sought to investigate the role of β-catenin signaling during this expansion phase. To this end, we performed neonatal knockout experiments by administering tamoxifen (10 mg) to nursing mothers of newborn (P0) control and ABKO pups ([@b27-0050503]), and analyzed the distribution of EYFP label in P7 infants and P30 juveniles.

The pancreata of neonatal ABKO mice were noticeably smaller than those of controls at P7 ([Fig. 2A,B](#f2-0050503){ref-type="fig"}) but not at P30 (data not shown). This might indicate that loss of β-catenin affects acinar cell expansion only during the first few days of life, or else that compensatory growth of unrecombined acinar cells eventually makes up for the deficiency imposed by β-catenin deletion. The latter possibility was supported by quantification of EYFP-labeled acinar cells, which revealed a twofold reduction in labeled ABKO acinar cells at P7, compared with control littermates ([Fig. 2C,D](#f2-0050503){ref-type="fig"}), increasing to a fivefold reduction by P30 ([Fig. 2E--G](#f2-0050503){ref-type="fig"}). At the latter stage, most acinar cells in ABKO pancreata remained EYFP negative and retained β-catenin expression ([Fig. 3A,B](#f3-0050503){ref-type="fig"}). These data indicate that β-catenin function is required for the normal expansion of postnatal acinar cell mass.

The relative deficiency of EYFP+ acinar cells, in the ABKO background, could be caused by any of several cellular defects, including loss of differentiation state, increased cell death and decreased proliferation. Although, under normal physiological conditions, adult acinar cells do not transdifferentiate into duct or islet cells ([@b13-0050503]; [@b53-0050503]), they can adopt a duct-like phenotype during cell culture ([@b12-0050503]; [@b35-0050503]), and in response to oncogenic and mitogenic signals in vivo ([@b2-0050503]; [@b10-0050503]; [@b22-0050503]; [@b25-0050503]; [@b38-0050503]). However, this did not seem to be the case for neonatal acinar cells that had lost β-catenin: as was found in the short-term adult labeling experiment described above ([Fig. 1](#f1-0050503){ref-type="fig"}), EYFP expression in P30 juvenile knockout pancreata identified cells that lacked β-catenin but retained normal expression of the acinar marker amylase ([Fig. 3A--D](#f3-0050503){ref-type="fig"}). Furthermore, although *ElaCreERT* induces a low level of ectopic recombination in insulin+ β-cells ([@b53-0050503]), we found no significant difference in the fraction of EYFP-labeled β-cells between control and ABKO pancreata \[control (*n*=2): 3.4±0.3% EYFP labeling of insulin+ cells; ABKO (*n*=2): 5.1±0.4% labeling of insulin+ cells; *P=*0.09\], suggesting that β-catenin-deficient acinar cells had not transdifferentiated to islets ([Fig. 3E,F](#f3-0050503){ref-type="fig"}). Finally, EYFP+ cells did not express the ductal marker CK19 in either control or ABKO backgrounds ([Fig. 3G,H](#f3-0050503){ref-type="fig"}). These data indicate that, although β-catenin is needed for acinar development in utero, its deletion after birth does not divert acinar cells to an alternative fate, but instead prevents their normal expansion during juvenile growth.

![**β-catenin is required for physiological expansion of acinar cells.** Control or ABKO mice received tamoxifen (TM) either on the day of birth, via maternal gavage, or as adults (P42), and were analyzed as neonates (P7), juveniles (P30) and adults (P63) (*n*=4--7 mice per genotype per time point). (A,B) At P7, pancreata of TM-treated ABKO mice are visibly smaller than those of control littermates (photographs taken at identical magnification). (C--F) Staining for EYFP lineage labeling (green) of amylase+ acinar cells (red) reveals relatively fewer EYFP+ cells in ABKO pancreata at P7 (C,D) and P30 (E,F), compared with controls. Scale bar: 100 μm. (G) The EYFP labeling index of amylase+ acinar cells is decreased at both time points in young ABKO mice, indicating that β-catenin-deficient acinar cells do not efficiently contribute to postnatal expansion of the exocrine pancreas. (H) Control and ABKO mice received tamoxifen at 6 weeks of age (P42) and were assayed for EYFP expression after a 3-week chase (P63). The EYFP labeling index of amylase+ acinar cells is decreased in ABKO pancreata, consistent with a requirement for β-catenin in the slow homeostatic expansion of acinar cells.](DMM007799F2){#f2-0050503}

![**Acinar cells maintain normal differentiation status in the absence of β-catenin.** Control or ABKO mice received tamoxifen at birth and were analyzed as juveniles (P30). (A,B) At P30, EYFP+ cells (green) co-express β-catenin (white) in control but not ABKO pancreata (closed and open arrowheads, respectively). (C,D) Both control and β-catenin-deficient ABKO pancreata maintain normal cytoplasmic amylase expression (red). (E,F) Leaky recombination within insulin+ β-cells (red) by *ElaCreERT* produces similar islet labeling in control and ABKO pancreata (arrowheads). (G,H) EYFP+ cells of control and ABKO pancreata do not co-express the duct marker CK19 (red). Arrowheads indicate adjacent, non-overlapping EYFP+ and CK19+ cells. Scale bars: 100 μm.](DMM007799F3){#f3-0050503}

β-catenin is required for proliferation of neonatal acinar but not islet cells
------------------------------------------------------------------------------

To determine whether the requirement for β-catenin in acinar expansion was manifested at the level of cell division, we compared control and β-catenin-deficient acinar cells for expression of the proliferation marker Ki67. Immunostaining revealed a fourfold relative decrease, compared with controls, in the fraction of EYFP-labeled acinar cells staining for Ki67 in ABKO pancreata at P7 ([Fig. 4](#f4-0050503){ref-type="fig"}). Although a compensatory increase in proliferation might be expected among those acinar cells that retain β-catenin in the ABKO pancreas, we found no significant change in the Ki67+ fraction of EYFP-negative (EYFP--) acinar cells between control (30.3±2.6%; *n*=5) and ABKO (30.5±1.4%; *n*=7; *P*=0.9) pancreata at this stage. It will be interesting to determine whether β-catenin-retaining acinar cells of ABKO pancreata exhibit a higher proliferation index at later stages, when overall proliferation declines in controls. In contrast to the dramatic proliferation phenotype of β-catenin-deficient cells, we found that EYFP+ acinar cells in ABKO pancreata were not subject to increased rates of apoptosis when compared with controls, as indicated by a similar (and very low) proportion of EYFP+ acinar cells co-expressing the apoptosis marker cleaved caspase-3 (cCasp3) at P7 \[control (*n*=2): 0.5±0.05%; ABKO (*n*=2): 0.7±0.4%; *P*=0.7\]. Because decreased cell division, even without increased death, would suffice to explain the impaired expansion of ABKO cells, we conclude that proliferation represents the major requirement for β-catenin in neonatal acinar cells.

Although β-catenin is needed to generate acinar cells in the embryonic pancreas, it is dispensable for islet cell specification ([@b39-0050503]). As noted in the Introduction, however, various studies have suggested a role for Wnt--β-catenin in postnatal islet growth or function ([@b8-0050503]; [@b32-0050503]; [@b45-0050503]). To determine whether islet and acinar cells share a requirement for β-catenin in proliferation, we deleted β-catenin in endocrine precursors specifically using a neurogenin-3 (*Ngn3*)*-Cre* BAC transgene ([@b47-0050503]). The resulting islet-specific β-catenin knockout (IsBKO) mice were recovered at weaning in normal mendelian ratios, and exhibited neither impaired survival nor glucose intolerance through ≥1 year of age (supplementary material [Fig. S1](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.007799/-/DC1)). We analyzed control and IsBKO pancreata for proliferation at P7, when islet as well as acinar cells undergo rapid proliferative expansion ([@b34-0050503]). Staining of IsBKO pancreata at this stage revealed normal organization of insulin+ β-cells and glucagon+ α-cells into islets devoid of β-catenin protein ([Fig. 5A--H](#f5-0050503){ref-type="fig"}). Furthermore, β-catenin-deficient islet cells proliferated indistinguishably from controls, as indicated by BrdU labeling ([Fig. 5I--K](#f5-0050503){ref-type="fig"}). These results support our prior finding that pan-pancreatic β-catenin deletion did not impair adult islet function ([@b39-0050503]) and suggest that, as is the case in utero, the major functional requirement for β-catenin after birth is specific to acinar cells. This specificity also indicates that β-catenin does not represent a 'housekeeping gene' for cell cycle progression that is required in all cell types.

β-catenin is required for homeostatic proliferation of acinar cells in the adult pancreas
-----------------------------------------------------------------------------------------

Whereas the juvenile pancreas grows rapidly, in parallel with the organism, the adult pancreas grows slowly and exhibits little turnover. Nonetheless, rare division of acinar cells can be observed in the adult ([@b34-0050503]; [@b56-0050503]), raising the question of whether this low level of proliferation also depends on β-catenin function. To determine whether β-catenin is required for acinar cell proliferation in the normal adult pancreas, we pulsed control and ABKO mice with tamoxifen at 6 weeks of age and assayed EYFP expression and proliferation at 9 weeks of age. To maximize the detection of rare S-phase events, we administered BrdU via the drinking water for 7 days prior to sacrifice, thereby capturing a week of cell proliferation in the adult pancreas ([@b56-0050503]). We found a modest but significant decrease in the fraction of EYFP+ acinar cells in ABKO pancreata compared with controls ([Fig. 2H](#f2-0050503){ref-type="fig"}), suggesting that loss of β-catenin prevents normal expansion of acinar cells. More dramatically, staining for BrdU revealed a tenfold reduction in the fraction of BrdU+ EYFP+ β-catenin-deficient acinar cells compared with controls ([Fig. 4F](#f4-0050503){ref-type="fig"}). Thus, we conclude that β-catenin is required not only for rapid acinar expansion in the juvenile pancreas, but also for steady-state proliferation in the adult.

![**Neonatal and adult acinar cell proliferation requires intact β-catenin function.** To determine whether β-catenin is required for acinar cell proliferation in the neonatal and adult pancreas, we pulsed mice with tamoxifen on the day of birth, via maternal gavage, or as adults (P42), and analyzed neonatal (P7) and adult (P63) pancreata, respectively. Prior to sacrifice, adult mice received a 7-day BrdU pulse to label proliferating cells. (A,B) Staining for EYFP+ acinar cells (green) reveals a reduction in β-catenin-deficient acini in ABKO pancreata. (C,D) The fraction of proliferating EYFP+ acinar cells, marked by anti-Ki67 antibody labeling (white arrowheads), is markedly decreased in ABKO mice (open arrowhead indicates Ki67-negative/EYFP+ acinar cells) compared with controls. Scale bar: 100 μm. (E) Quantification of the Ki67 labeling index of EYFP+ cells reveals a significant reduction in the proliferative capacity of β-catenin-deficient acini compared with controls (*n*=5--7 mice per genotype). (F) Staining for BrdU revealed an approximately tenfold reduction in the fraction of BrdU-labeled EYFP+ cells in ABKO mice compared with controls, indicating a loss of proliferative ability in the resting adult pancreas (*n*=4--5 mice per genotype).](DMM007799F4){#f4-0050503}

Loss of β-catenin does not sensitize adult acinar cells to pancreatitis-associated injury
-----------------------------------------------------------------------------------------

The pancreas is capable of at least partial regeneration from a variety of injuries, including acute pancreatitis induced by supraphysiological levels of the acinar secretagogue caerulein ([@b61-0050503]). Regeneration in this model is preceded by transient expression of progenitor-like markers, including Pdx1 ([@b17-0050503]; [@b24-0050503]; [@b38-0050503]), suggesting that re-establishment of acinar cell mass involves a genetic program similar to that of embryonic acinar development. Indeed, it is reported that pancreas-specific β-catenin knockout mice (generated using a *Ptf1a^Cre^* deleter strain) exhibit an almost complete loss of acinar cells after caerulein treatment ([@b38-0050503]). To determine the cell-autonomous requirement for β-catenin during injury and regeneration, we induced a pulse of acinar-specific recombination by tamoxifen treatment (10 mg) of adult control and ABKO mice, waited 1 week, and induced pancreatitis by a 2-day course of caerulein treatment ([@b24-0050503]).

![**Islet cells develop and proliferate independently of β-catenin status.** Neonatal (P7) control (*Ctnnb1^lox/+^; Ngn3-Cre*) and islet-cell-specific β-catenin knockout (IsBKO: *Ctnnb1^Δ/lox^; Ngn3-Cre*) mice were administered BrdU 1 hour prior to sacrifice and analyzed by immunofluorescence. (A--D) Islets of control mice exhibit clear β-catenin staining (red) in both insulin+ β-cells (green) and glucagon+ α-cells (white). Dashed lines in A indicate the area magnified in B--D. White and yellow arrowheads indicate insulin+ and glucagon+ cells, respectively, expressing β-catenin (closed; B--D) or lacking β-catenin (open; F--H). (E--H) Islet morphology and marker expression is normal in IsBKO pancreata, despite loss of β-catenin in β- and α-cells. (I,J) Anti-BrdU staining (red) reveals a similar distribution of proliferating cells among control and IsBKO endocrine cells. Arrowheads denote BrdU+/insulin+ β-cells. (K) Quantification reveals no significant difference in BrdU labeling of β-cells between control and IsBKO mice (*n*=2 mice per genotype; *P*=0.97). Scale bar: 100 μm.](DMM007799F5){#f5-0050503}

Whereas saline-treated pancreata appeared normal at all time points, pancreata of mice that were administered caerulein exhibited clear abnormalities at 2 days post-treatment, including fibroblast and leukocyte infiltration ([Fig. 6A--D](#f6-0050503){ref-type="fig"}), and acinar-ductal metaplasia indicated by co-expression of amylase with the duct marker CK19 (supplementary material [Fig. S2](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.007799/-/DC1)). Previous studies have demonstrated that acinar cells undergoing pancreatitis-induced metaplasia upregulate Pdx1, a transcription factor normally expressed in progenitor cells, while maintaining expression of Ptf1a, a master regulator of acinar cell identity ([@b24-0050503]; [@b37-0050503]). Both of these phenomena were observed identically between control and β-catenin-deficient acinar cells, confirming that loss of β-catenin does not disrupt the differentiation state of regenerating acinar cells (supplementary material [Fig. S3](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.007799/-/DC1)). Importantly, there was also no difference in the fraction of EYFP+ acinar cells between ABKO and control mice at the 2-day post-caerulein time point, indicating that loss of β-catenin did not affect the ability of acinar cells to survive pancreatitis-associated injury ([Fig. 6E--I](#f6-0050503){ref-type="fig"}).

As an independent indicator of pancreatic injury, we assayed serum amylase levels before and after treatment, and found that caerulein-treated mice of both genotypes exhibited a transient increase in serum amylase 1 hour after the last caerulein injection, with a return to baseline 1 day later (supplementary material [Fig. S4](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.007799/-/DC1)). Finally, staining for the apoptotic marker cCasp3 revealed quantitatively similar overlap with EYFP+ acinar cells in control and ABKO pancreata, indicating that pancreatitis-associated injury was not more likely to trigger apoptosis of β-catenin-deficient acinar cells than in control cells ([Fig. 6J--L](#f6-0050503){ref-type="fig"}). Taken together, our results indicate that pancreatitis is not aggravated by deletion of β-catenin specifically in acinar cells, in contrast to a previous study of mice with pan-pancreatic β-catenin deficiency ([@b38-0050503]).

![**β-catenin-deficient acinar cells are not preferentially injured during caerulein-induced pancreatitis.** Control and ABKO mice received tamoxifen at 2 months of age and were treated with caerulein 1 week later to induce acute pancreatitis. The extent of acinar cell regeneration was analyzed histologically on wax sections, and quantitatively by immunofluorescence on frozen sections. (A--D) 2 days after the injection series was complete, H&E staining revealed no abnormalities in the pancreata of saline-treated mice, and a similar appearance of overall injury between caerulein-treated control and ABKO mice. At this stage, acute pancreatitis is manifested by infiltrating fibroblasts and inflammatory cells (black arrowheads) and the presence of dilated, metaplastic acini (open arrowheads). is, islet; du, duct. (E--H) A similar extent and distribution of EYFP labeling (green) is observed among amylase+ acinar cells (red) of saline- and caerulein-treated mice, regardless of genotype. (I) Quantification reveals no significant difference in the percentage of *R26R^EYFP^*-labeled acinar cells, between treatments or genotypes (*n*=4--5 mice per genotype per treatment group). (J--L) At 2 days after caerulein treatment, double-staining for EYFP (green) and the apoptosis marker cleaved caspase-3 (red) reveals no increase in apoptosis among *R26R^EYFP^*-labeled acinar cells of control and ABKO mice (*n*=3 mice per genotype). White arrowheads indicate cCasp3+ cells, co-expressing EYFP (closed) or unlabeled (open). Scale bars: 100 μm.](DMM007799F6){#f6-0050503}

β-catenin is required for acinar cell proliferation during regeneration
-----------------------------------------------------------------------

Previous studies have found substantially complete acinar regeneration within 7 days following caerulein treatment ([@b17-0050503]; [@b24-0050503]). To look specifically at regeneration, we analyzed control and ABKO pancreata 14 days after saline or caerulein administration, from mice treated in parallel to those analyzed at the 2-day time point. The appearance of these pancreata was grossly indistinguishable between genotype and treatment groups, and the histology of 14-day post-caerulein ABKO pancreata was similar to that of caerulein-treated controls ([Fig. 7A--D](#f7-0050503){ref-type="fig"}). This result differs from the almost complete involution and fatty replacement of acinar tissue found after caerulein treatment of mice with a pan-pancreatic deletion of β-catenin (using *Ptf1a^Cre^*) ([@b38-0050503]).

Examination of EYFP labeling at the 14-day time point, however, revealed a dramatic decrease in the labeling index of ABKO acinar cells following regeneration ([Fig. 7E--I](#f7-0050503){ref-type="fig"}). As in the neonatal labeling experiments, residual EYFP+ acinar cells were β-catenin deficient, yet exhibited a normal differentiated acinar phenotype (supplementary material [Fig. S5](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.007799/-/DC1)).

In both genotypes, normalization of organ morphology was accompanied by resolution of metaplasia, as indicated by downregulation of the duct marker CK19 in EYFP+ acinar cells (supplementary material [Fig. S2](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.007799/-/DC1)). As noted above, β-catenin-deficient and control acinar cells exhibited similar levels of apoptosis following caerulein administration, suggesting that cell death did not prevent mutant cells from contributing to regeneration. Instead, we found a major defect in proliferation: administering BrdU 1 hour prior to sacrifice revealed a dramatic decrease in S-phase cells among EYFP+/β-catenin-deficient acinar cells at 2 days post-caerulein treatment ([Fig. 7J--L](#f7-0050503){ref-type="fig"}). As in juvenile mice, we did not observe evidence for a compensatory increase in the proliferation index of EYFP-negative acinar cells \[control + caerulein (*n*=4): 1.8±0.26%; ABKO + caerulein (*n*=4): 1.6±0.35%; *P*=0.6\]. The fraction of wild-type acinar cells incorporating BrdU was relatively low at this early time point, leaving open the possibility that an additional defect in survival, manifested at an intermediate time point not yet analyzed, could have contributed to the ultimate decrease in ABKO acinar cells at 14 days post-caerulein. Alternatively, the window of wild-type acinar cell proliferation might be extended when a substantial fraction of the pancreas comprises ABKO cells, such that even a relatively low wild-type proliferation rate could produce dramatic out-competition of ABKO cells. In any event, the overall agreement between these results and our findings in neonatal and uninjured adult mice indicate a continuous requirement for β-catenin in acinar cell proliferation, during both physiological and regenerative growth.

![**β-catenin is required for regenerative expansion of acinar cells.** (A--D) 14 days after treatment with saline or caerulein, H&E staining reveals comparable regeneration and resolution of fibrosis in control and ABKO mice subjected to acute pancreatitis. is, islet; du, duct. (E--I) EYFP labeling (green) is similar between saline and caerulein-treated control mice, whereas the fraction of EYFP+ acinar cells is dramatically reduced in ABKO pancreata (*n*=5--7 mice per genotype and treatment group; *P*\<0.0006). (J--L) Control and ABKO mice were administered a 1-hour BrdU pulse, at 2 days post-caerulein treatment, sacrificed and analyzed for labeling. The fraction of BrdU+ *R26R^EYFP^*-labeled cells is significantly reduced in ABKO pancreata, indicating decreased acinar cell proliferation following acute pancreatitis (*n*=3 mice per genotype; *P*\<0.05). Scale bars: 100 μm.](DMM007799F7){#f7-0050503}

DISCUSSION
==========

During postnatal growth and regeneration of the pancreas, new acinar cells are generated almost exclusively from the division of pre-existing acinar cells ([@b13-0050503]; [@b53-0050503]). β-catenin has an established role in the embryonic development of acinar cells ([@b39-0050503]; [@b58-0050503]); however, whether this requirement applies after birth has not been addressed. Here we demonstrate a continuous requirement for β-catenin in the establishment and maintenance of acinar cell mass, extending from organogenesis in the embryo through expansion and homeostasis in the juvenile and adult organ, as well as regeneration following injury.

To our knowledge, this is the first study to interrogate the specific requirement for β-catenin in adult acinar cells. In several respects, our findings extend those of others and ourselves. First, we and others have shown that β-catenin deletion during organogenesis reduces acinar cell number at birth and beyond ([@b38-0050503]; [@b39-0050503]; [@b58-0050503]). Here, we demonstrate a continued requirement for β-catenin after birth, operating at the level of proliferation rather than specification or differentiation. Recent studies indicate that acinar-like 'tip cells' of the embryonic pancreas represent multipotent progenitors that contribute to islets and ducts for the first several days of pancreatic organogenesis ([@b64-0050503]). It is tempting to speculate that immature tip cells also require β-catenin for proliferative expansion, the failure of which partly explains the embryonic β-catenin deletion phenotype.

As well as acinar cells, we investigated the role of β-catenin in postnatal islet cells; none was detectable. This result agrees with prior studies of adult, pan-pancreatic β-catenin knockout mice, which exhibit normal glucose homeostasis ([@b14-0050503]; [@b39-0050503]; [@b58-0050503]), but contradicts the emerging hypothesis that β-catenin promotes proliferation or function of insulin-producing β-cells ([@b33-0050503]; [@b59-0050503]). Evidence supporting this hypothesis includes β-cell hypoplasia following misexpression of the β-catenin inhibitor Axin ([@b45-0050503]), and perinatal lethality observed when β-catenin is deleted with an insulin-promoter-driven *Cre* transgene (*RIP-Cre*) ([@b8-0050503]). Both of these experiments have the potential for non-specific effects, however. In addition to β-catenin, Axin has been found to inhibit activin--TGF-β signaling through Smad3 ([@b21-0050503]), the latter of which is required for postnatal β-cell expansion ([@b49-0050503]). The *RIP-Cre* transgene, meanwhile, has been shown to induce widespread recombination in the brain ([@b60-0050503]) and to confer metabolic phenotypes independent of deletion in β-cells ([@b30-0050503]). In our hands, *Ngn3-Cre* drives highly efficient deletion of β-catenin in islet cells without apparent phenotype, suggesting that results obtained with *RIP-Cre* must be interpreted cautiously.

Human genetics provides indirect evidence linking Wnt--β-catenin signaling to islet function, because non-coding single-nucleotide polymorphisms (SNPs) in *TCF7L2*, a transcription factor partner of β-catenin, are associated with type-2 diabetes risk ([@b18-0050503]). Because distinct TCF7L2 isoforms can promote or inhibit Wnt signaling, including within islet cells ([@b29-0050503]; [@b55-0050503]; [@b57-0050503]), it is hard to predict how *TCF7L2* polymorphisms might modulate Wnt pathway output, and whether the effects relevant to diabetes are played out in β-cells or in peripheral tissues. Although our results indicate that Wnt--β-catenin signaling is not essential to β-cell function, it will be important to determine whether β-catenin-deficient islet cells adapt normally to metabolic stressors implicated in type-2 diabetes.

Our finding that β-catenin is required differentially in mouse acini and islets emphasizes its cell-type-dependent role in proliferation. Gain-of-function studies similarly indicate that hyperactivation of β-catenin signaling promotes acinar but not islet expansion ([@b23-0050503]; [@b54-0050503]). Although information on growth control in the human pancreas remains scarce, autopsy-based studies suggest that β-cell and exocrine mass expand with distinct kinetics during childhood ([@b36-0050503]), supporting the hypothesis that proliferation in these compartments is controlled by different mechanisms. Although some aspects of organ growth control might be species specific, our finding that β-catenin is required for all phases of mouse acinar proliferation, from neonatal growth to adult homeostasis and regeneration, suggests that this action of β-catenin is fundamental and ancestral. Studies of rare pancreatic cancer subtypes provide direct evidence for a conserved and acinar-specific role of β-catenin in humans: mutational activation of β-catenin signaling is observed in acinar cell carcinomas but not insulinomas ([@b1-0050503]), suggesting that the former cancer exploits the proliferation control circuits of its untransformed precursors.

The cell of origin for acinar carcinoma remains unknown, and the activation of β-catenin in this cancer could reflect a role for this pathway in promoting acinar cell identity rather than proliferation per se. Our studies, however, indicate that β-catenin is not required for the phenotypic maintenance of acinar cells, even following injury. During experimental pancreatitis, in particular, we find that β-catenin-deficient and control acinar cells behave similarly in all respects except proliferation. By contrast, Morris et al. found that mice with pan-pancreatic β-catenin deletion, driven by *Ptf1a^Cre^*, exhibit a more severe response to experimental pancreatitis, including sustained loss of acinar cells ([@b38-0050503]). The difference between this model and ours could reflect the fact that the *Ptf1a^Cre^* produces complete β-catenin ablation in acinar cells, whereas a considerable fraction of acinar cells retains β-catenin in ABKO mice. Alternatively, the more severe phenotypes observed with *Ptf1a^Cre^* could reflect recombination in non-acinar cells, including ducts ([@b26-0050503]). Intact duct cell function is required for maintenance of the entire exocrine compartment, as indicated by deletion of the ciliogenesis regulator *Kif3a* ([@b5-0050503]). Although primary cilia are found only on duct cells, their ablation produces a pancreatitis-like phenotype that includes non-cell-autonomous acinar cell death. Interestingly, *Kif3a* knockout mice exhibit fat infiltration into the exocrine pancreas, a phenotype that is frequently seen in severe human pancreatitis ([@b3-0050503]) and which can be observed even in uninjured, pan-pancreatic β-catenin knockout mice ([@b38-0050503]; [@b58-0050503]) (L.C.M., unpublished data). We have never observed this phenotype in ABKO mice, suggesting that it reflects a role of β-catenin in multipotent progenitor or mature duct cells, rather than a cell-autonomous function in maintaining acinar survival or differentiation.

The downstream effectors of β-catenin in acinar cells remain undefined, although the Wnt--β-catenin target gene *Myc* is a strong candidate because its deletion abolishes the exocrine hyperplasia of *Apc* knockout mice ([@b54-0050503]). The apparently reciprocal phenotypes observed upon deletion and activation of β-catenin suggest that it acts as a signaling molecule in the pancreas, although we note that β-catenin can function independently of Wnt ligands ([@b40-0050503]). Although additional experiments will be required to determine the precise role of Wnt proteins per se in acinar proliferation, small-molecule modulators of β-catenin signaling are increasingly available ([@b43-0050503]) and could be clinically useful. Human pancreatitis, both acute and chronic, is associated with acinar cell proliferation ([@b16-0050503]; [@b65-0050503]). By enhancing proliferation, pharmacological β-catenin agonists might enhance regeneration and improve the outcome of acute pancreatitis. By contrast, clinical observations indicate that the pain of chronic pancreatitis will occasionally decline in parallel with a decline in acinar cell function, possibly due to the 'burn-out' of residual acinar cells ([@b46-0050503]). By inhibiting regeneration, β-catenin antagonists might accelerate this phenomenon, and perhaps limit overall disease severity. Given that Wnt--β-catenin signaling is active and important in other adult tissues, such as the intestine, effective interventions might require identifying pancreas-specific effectors of this pathway. Nonetheless, the widely used psychiatric agent lithium is now recognized as a potent activator of β-catenin, owing to its inhibition of the GSK3 kinase ([@b41-0050503]). The fact that patients tolerate long-term lithium treatment suggests that a degree of Wnt--β-catenin modulation can be achieved without prohibitive side effects.

We note that the specific and circumscribed phenotypes of ABKO mice contrast with those of knockouts in other developmental signaling cascades, including Notch and Hedgehog. Inhibiting these pathways, in the context of pancreatitis, causes increased cell death and prevents the resolution of metaplasia ([@b17-0050503]; [@b48-0050503]), implying that small molecules targeting Notch or Hedgehog will have pleiotropic effects, including the alteration of differentiation states. We and others have shown that acinar cells transdifferentiate during *Kras*-induced initiation of pancreatic ductal adenocarcinoma, and that this process is accelerated by pancreatitis ([@b6-0050503]; [@b10-0050503]; [@b9-0050503]; [@b22-0050503]; [@b25-0050503]; [@b38-0050503]), emphasizing the importance of studying the mechanisms controlling growth and maintenance of this cell type. Understanding the cell-autonomous and non-autonomous roles of β-catenin in acinar cell expansion, injury and regeneration might shed light on the linked etiologies of pancreatitis and pancreatic cancer, as well as identify a molecular pathway that could be harnessed in treating these generally intractable conditions.

METHODS
=======

Mouse breeding and genetic manipulation
---------------------------------------

All mouse experiments were performed according to a protocol approved by the University of Utah IACUC. The following mice were obtained from the Jackson Laboratories: floxed and germline β-catenin loss-of-function mice (*Ctnnb1^tm2Kem/J^* and *Ctnnb1^tm2.1Kem^*; referred to here as *Ctnnb1^lox^* and *Ctnnb1^Δ^*, respectively) ([@b4-0050503]); the Cre-dependent EYFP reporter strain *Gt(ROSA)26Sor^tm1(EYFP)Cos^* ([@b51-0050503]), referred to here as *R26R^EYFP^*; and *Ngn3Cre* BAC transgenic mice ([@b47-0050503]). *Pdx1Cre* and *Elastase-CreERT* (*ElaCreERT*) transgenic mice ([@b20-0050503]; [@b39-0050503]; [@b52-0050503]) were provided by Doug Melton (Harvard University, MA). *Ctnnb1^Δ^* and *Cre* transgenic lines were maintained by outcrossing to CD-1 wild-type mice, whereas the *Ctnnb1^lox^* and *R26R^EYFP^* alleles were maintained by inbreeding on a mixed CD-1 × C57BL/6 background. Unless otherwise noted, experiments were performed in young adult mice, 8--12 weeks in age at the outset of any treatment. To activate recombination by *ElaCreERT*, we administered tamoxifen (Sigma), dissolved in corn oil, by oral gavage.

Glucose tolerance tests
-----------------------

Mice were fasted overnight with access to water and injected with D-glucose at 2 mg/g body weight. Blood was drawn from a tail incision before glucose injection and at indicated time points post-injection, and read with an Ascencia Contour glucometer (Bayer). Net area-under-curve (AUC) values were calculated by the trapezoidal rule. Results are reported as mean ± s.e.m.

Caerulein treatment
-------------------

We induced acute pancreatitis by caerulein treatment of 2-month-old male and female mice, conditionally null for β-catenin (*Ctnnb1^Δ/lox^; R26R^EYFP/+^; ElaCreERT*) as well as control littermates (*Ctnnb1^+/lox^; R26R^EYFP/+^; ElaCreERT*). Following an established protocol ([@b24-0050503]), mice received repeated intraperitoneal (i.p.) injections of caerulein (Bachem; 0.1 μg/g in 0.8% NaCl) eight times daily over 2 days (16 injections total). Negative controls were injected in parallel with saline alone. We refer to the last day of injections as 'day 0', such that mice sacrificed 48 hours after the last injection would constitute the 2-day post-treatment group. To monitor serum amylase levels, cheek bleeds of approximately 100μl were drawn, chilled on ice and clarified by centrifugation. Serum samples were diluted 1:4 with PBS, and 7 μl of diluted serum mixed with 280 μl Infinity serum amylase reagent (Thermo-Fisher) prior to analysis on a VMax Kinetic microplate reader (Molecular Devices).

Tissue processing and staining
------------------------------

Mice were euthanized with isoflurane, and tissues were dissected into ice-cold PBS for further processing. BrdU labeling was used to identify proliferating cells, either by injecting mice with BrdU (50 μg/g body weight) at 1 hour prior to sacrifice, or by administering it in the drinking water (1 mg/ml) over 7 days. Pancreata were dissected into multiple fragments and fixed either for paraffin sections \[zinc-buffered formalin (Polysciences), overnight\] or frozen sections (4% paraformaldehyde/PBS; 4°C 2--4 hours), followed by processing as previously described ([@b27-0050503]; [@b39-0050503]). Paraffin sections were cut at 6 μm thickness and collected serially such that sections were spaced approximately 50--80 μm apart, spanning the entire specimen. Frozen sections were cut at 8 μm thickness, and similarly collected such that sections were spaced approximately 60--100 μm apart, spanning the entire specimen.

Primary antibodies used for immunostaining are listed in supplementary material [Table S1](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.007799/-/DC1), and secondary antibodies (raised in donkey) were obtained from Jackson ImmunoResearch. Immunohistochemistry and immunostaining were performed as previously described ([@b27-0050503]; [@b39-0050503]), with all paraffin sections subjected to high-temperature antigen retrieval. To detect Ki67 and BrdU, sections were subjected to digestion with DNAse I (700 u/μl, in 40 mM Tris-HCl pH 7.4, 10 mM NaCl, 6 mM MgCl~2~, 10 mM CaCl~2~) for 15 minutes at room temperature ([@b62-0050503]). Slides stained by immunofluorescence were mounted with Fluoromount-G (Southern Biotech) and imaged on an Olympus IX71 microscope. Photomicrographs were produced with MicroSuite software (Olympus) and processed in Adobe Photoshop, with exposure times and adjustments identical between treatment groups.

###### TRANSLATIONAL IMPACT

**Clinical issue**

Understanding how growth and regeneration of the pancreas are controlled should provide new insights into the etiology and treatment of diseases that affect this organ, including diabetes, pancreatic cancer and pancreatitis. The latter two of these seem to be linked: recent work indicates that pancreatitis can promote acinar cell reprogramming into pancreatic ductal tumors. The Wnt signaling pathway (in which β-catenin is a key mediator) is a crucial regulator of embryonic acinar cell development, but its role in the mature pancreas is more controversial. The numerous proposed roles of β-catenin in both endocrine and exocrine cells of the pancreas are complex and controversial. Some conflicting results have been obtained by manipulating the mouse β-catenin gene with various *Cre* deleter transgenes, most of which are active in multipotent progenitor cells. In this study, the authors sought to strictly define the genetic requirement for β -catenin in the postnatal pancreas, particularly in establishing, maintaining and regenerating its most abundant constituent, the acinar cell.

**Results**

The authors developed a quantitative 'pulse-chase' knockout and labeling approach to analyze β-catenin function specifically in differentiated acinar cells during their expansion and regeneration. Using this system, they find that β-catenin-deficient acinar cells are dramatically impaired in their ability to proliferate during normal juvenile growth and adult homeostasis, as well as during regeneration from injury caused by experimental pancreatitis. However, β-catenin deletion in acinar cells does not cause cell death or dedifferentiation, nor render the organ more vulnerable to injury. Importantly, the requirement of β-catenin for proliferation seems to be acinar cell specific, because its deletion in islet cells does not detectably impair their expansion or metabolic function.

**Implications and future directions**

These results clarify the cell-type specificity of β-catenin function in vivo, which can be detected only through a lineage-restricted deletion approach. The Wnt--β-catenin pathway has been implicated in regeneration and tumorigenesis of other tissues, and it is becoming increasingly amenable to pharmacological manipulation as new drugs are developed. For example, small-molecule activators of β-catenin signaling already exist, and this study suggests that they could be useful in accelerating recovery from acute pancreatitis. By contrast, β-catenin inhibitors might prevent the continuous regeneration that sustains chronic pancreatitis. The specificity of β-catenin action implies that such interventions will not affect differentiation state, and therefore should not increase cancer risk. Given that the absence of β-catenin did not disrupt islet cell growth or function, these results also suggest that type-2-diabetes-associated mutations in *TCF7L2* (encoding a β-catenin binding partner) might influence diabetes risk via functions other than in the pancreas. Future studies will focus on the molecular mechanisms upstream and downstream of β-catenin in acinar cells, and address the translational potential of β-catenin-focused intervention in disease models.

Image quantification and analysis
---------------------------------

To determine *R26R^EYFP^* labeling indices, we photographed six to ten independent fields (20× or 40× original magnification) per specimen, across multiple sections. Using ImageJ software (NIH), cells co-expressing a given differentiation marker with EYFP were detected by additive image overlay of the DAPI channel with anti-GFP and anti-marker immunofluorescence, and counted using the Analyze Particles function, as described previously ([@b27-0050503]). Random samples were scored manually in Adobe Photoshop, to confirm overall counting accuracy. Under staining conditions in which additive image overlay was inaccurate, we scored samples manually in Adobe Photoshop CS5, using the Analysis\>Count Tool function. Calculations were performed in Microsoft Excel, and all results are reported as mean ± s.e.m. *P*-values were calculated by two-tailed, unpaired *t*-test.

Supplementary Material
======================
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